Feasibility of Biowaiver Extension to Biopharmaceutics Classification System Class III Drug Products

[1]  Jennifer B Dressman,et al.  Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[2]  Lawrence X. Yu,et al.  Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[3]  A. Marzo,et al.  Open questions on bioequivalence: the case of multiple peak phenomenon , 2004, The Journal of pharmacy and pharmacology.

[4]  T. Dowling,et al.  Validation of a simplified method for determination of cimetidine in human plasma and urine by liquid chromatography with ultraviolet detection. , 2004, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  Fridrun Podczeck,et al.  Influence of Polyethylene Glycol 400 on the Gastrointestinal Absorption of Ranitidine , 2002, Pharmaceutical Research.

[6]  R. Löbenberg,et al.  Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  B. Schug,et al.  The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver? , 1999, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[8]  J. Witcher,et al.  Applications and Simulations of a Discontinuous Oral Absorption Pharmacokinetic Model , 1996, Pharmaceutical Research.

[9]  G L Amidon,et al.  Novel approach to the analysis of in vitro-in vivo relationships. , 1996, Journal of pharmaceutical sciences.

[10]  I. Wilding,et al.  The effect of mannitol on the oral bioavailability of cimetidine. , 1995, Journal of pharmaceutical sciences.

[11]  Gordon L. Amidon,et al.  Gastric pH Influences the Appearance of Double Peaks in the Plasma Concentration-Time Profiles of Cimetidine After Oral Administration in Dogs , 1995, Pharmaceutical Research.

[12]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[13]  G. Amidon,et al.  Variable gastric emptying and discontinuities in drug absorption profiles: Dependence of rates and extent of cimetidine absorption on motility phase and pH , 1994, Biopharmaceutics & drug disposition.

[14]  Shein-Chung Chow,et al.  Design and Analysis of Bioavailability and Bioequivalence Studies , 1994 .

[15]  A. Parr,et al.  Effect of Sodium Acid Pyrophosphate on Ranitidine Bioavailability and Gastrointestinal Transit Time , 1993, Pharmaceutical Research.

[16]  A. Somogyi,et al.  Clinical Pharmacokinetics of Cimetidine , 1983, Clinical pharmacokinetics.

[17]  D. Johnson,et al.  Convenient and sensitive high-performance liquid chromatography assay for cimetidine in plasma or urine. , 1981, Journal of chromatography.

[18]  R. Miller,et al.  Pharmacokinetics and bioavailability of cimetidine in humans. , 1980, Journal of pharmaceutical sciences.

[19]  W. C. Randolph,et al.  High-pressure liquid chromatographic analysis of cimetidine, a histamine H2-receptor antagonist, in blood and urine. , 1977, Journal of pharmaceutical sciences.

[20]  Margareth R. C. Marques.  Dissolution Media Simulating Fasted and Fed States , 2004 .

[21]  Brian Tomlinson,et al.  A Modified Two-Portion Absorption Model to Describe Double-Peak Absorption Profiles of Ranitidine , 2003, Clinical pharmacokinetics.

[22]  Lawrence J Lesko,et al.  Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. , 2002, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[23]  J. Polli.  IVIVR versus IVIVC , 2000 .

[24]  J. Polli.  In vitro-in vivo relationships of several "immediate" release tablets containing a low permeability drug. , 1997, Advances in experimental medicine and biology.